Boundless Bio Investor Relations Material
Latest events
Status Update
Boundless Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Boundless Bio Inc
Access all reports
Boundless Bio Inc., trading under the NASDAQ symbol BOLD, is a clinical-stage oncology company focused on developing novel cancer treatments. The company leverages its proprietary Spyglass platform to target extrachromosomal DNA (ecDNA), which plays a significant role in oncogene amplification in over 14% of cancer patients. By identifying and inhibiting targets essential for ecDNA functionality, Boundless Bio aims to develop ecDNA-directed therapeutic candidates (ecDTx) designed to selectively eliminate cancer cells containing ecDNA without harming healthy cells. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
BOLD
Country
🇺🇸 United States